Synageva BioPharma Corp. (“Synageva”) GEVA, a
biopharmaceutical company developing therapeutic products for rare
disorders, today announced the pricing of its previously announced
underwritten public offering of common stock consisting of 2.75 million
shares at $56.63 per share. In connection with this offering, Synageva
granted to the underwriters a 30-day option to purchase 412,500
additional shares of common stock. If the underwriters exercise this
option, Synageva will have offered approximately 3.16 million shares of
its common stock.
Goldman, Sachs & Co. is acting as the sole book-running manager in the
offering. Morgan Stanley & Co., Cowen and Company, and Canaccord Genuity
Inc. are acting as co-managers in the offering.
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in